A Growing Drug Class: CGRP Antagonists for Migraine Headache Prevention
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A class of drugs known as CGRP antagonists is growing for the prevention of migraine headaches. The market for migraine treatments is expected to expand, with estimates suggesting it could reach between $12.5 billion and $16.4 billion by 2033. The potential of CGRP antagonists may also extend to treating pain indications beyond migraine.
Full coverage
1
Fortune Business Insights·Jun 292
Market.us·Oct 103
PR Newswire UK·May 254
The Transmitter·Dec 155
Fact.MR·Oct 206
Fierce Pharma·Aug 157
MedCentral·Nov 98
Clinical Trials Arena·Sep 5